Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07919951
NA

RAPID for Unresectable Colorectal Liver Metastases

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if the RAPID procedure works to treat colorectal cancer that has spread to the liver and cannot be removed by surgery. It will also learn about the safety of the procedure. The main questions it aims to answer are: 1. How many participants are alive without the cancer progressing or returning 2 years after the first-stage surgery? 2. How many participants complete the second-stage surgery, and how quickly does the liver graft grow between the two stages? 3. What medical problems do participants have around the time of surgery, including serious complications? Participants will: 1. Undergo the first-stage surgery: removal of the left part of the liver and implantation of a small liver graft, with the right portal vein tied off to help the graft grow; 2. Have blood tests and ultrasound checks after surgery, and regular CT or MRI scans to measure graft growth; (4) Undergo the second-stage surgery to remove the remaining diseased liver once the graft has grown enough (5) Visit the clinic every 3 months for up to 2 years after the second-stage surgery for checkups, imaging, and blood tests to see if the cancer has returned

Official title: Efficacy of the RAPID Procedure (Resection and Partial Liver Transplantation With Delayed Total Hepatectomy) for Unresectable Colorectal Liver Metastases: A Prospective Clinical Study

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-12-30

Completion Date

2030-12-01

Last Updated

2026-11-05

Healthy Volunteers

No

Interventions

PROCEDURE

RAPID Procedure

Two-stage surgical procedure combining the principles of ALPPS with auxiliary partial liver transplantation. Stage 1 (Day 0): partial hepatectomy to remove the tumor-bearing liver portion, orthotopic implantation of a small-for-size graft (living donor left lateral segments or split deceased-donor left lateral segments), and ligation of the portal vein supplying the preserved native liver; the corresponding hepatic artery is preserved. Interstage monitoring includes liver function tests, Doppler ultrasound, and CT/MRI volumetry. Stage 2: completion hepatectomy of the remnant native liver once the graft has achieved adequate volume and function.

Locations (1)

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China